Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.35 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12739711 | 0.92 | KDM1A (0.38) | KDM1AALDH1A1HCRTR1HCRTR2CALM1 | |
| SCHEMBL12739709 | 0.92 | KDM1A (0.38) | KDM1AALDH1A1HCRTR1HCRTR2CALM1 | |
| SCHEMBL12739724 | 0.90 | GLA (0.37) | SCN9AHTR6 | |
| SCHEMBL14766317 | 0.90 | KDM1A (0.37) | KDM1AALDH1A1HCRTR1HCRTR2CALM1 | |
| SCHEMBL12739720 | 0.90 | KDM1A (0.37) | KDM1AALDH1A1HCRTR1HCRTR2CALM1 | |
| SCHEMBL14766737 | 0.90 | BACE1 (0.39) | KDM1AHCRTR1HCRTR2CALM1 | |
| SCHEMBL12739726 | 0.89 | S1PR1 (0.38) | SCN9A | |
| SCHEMBL12739714 | 0.89 | KDM1A (0.36) | KDM1AHCRTR1HCRTR2CALM1FFAR4 | |
| SCHEMBL10303097 | 0.89 | CALM1 (0.41) | ALDH1A1CALM1 | |
| SCHEMBL12739732 | 0.89 | S1PR1 (0.40) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | KDM1A 937/4885ALDH1A1 1480/4885HCRTR1 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.